5-HT1A Receptor Agonist 8-OH-DPAT Improves Dyskinesias in Parkinson's Disease by Mitigating GluR1Ser831 Phosphorylation

Mao-Wen BA,Zhen-Guo LIU,Min KONG,Hong-Qi YANG,Sheng-Di CHEN,Guo-Qiang LU

DOI: https://doi.org/10.3969/j.issn.1008-0678.2006.06.002

2006-01-01

Abstract:Aim: To investigate effects of 5-HT1A receptor agonist 8-OH-DPAT on cellular morphology and behaviors in a rat model of levodopa-induced dyskinesias. Methods: The hemi-parkinsonian rat model was produced by injecting stereotaxically 6-OHDA to right medial forebrain bundle (MFB). Two sets of experiments were performed. In the first set, rats were treated with levodopa (50 mg·kg-1 with benserazide 12.5 mg·kg-1, twice daily), intraperitoneally (ip) for 22 days. On day 23, rats were divided randomly into three groups and received 8-OH-DPAT (1 mg·kg, ip), 8-OH-DPAT plus WAY-100635 (0.1 mg·kg-1, ip) and vehicle with each levodopa dose, respectively. In the second set, rats were divided randomly into two groups and were treated with levodopa (50 mg·kg-1, ip) plus 8-OH-DPAT (1 mg·kg-1, ip) and levodopa (50 mg·kg-1, ip) plus vehicle, respectively administered twice daily for 22 consecutive days. Peak rotation was estimated. Subcellualr distribution of GluR1 and GluR1Ser831 phosphorylation were observed by Western blot. Results: 8-OH-DPAT mitigated peak rotation. The effect of 8-OH-DPAT on dyskinesias could be eliminated by co-administration of WAY-100635, a 5-HT1A receptor antagonist. Moreover, 8-OH-DPAT could regulate subcellular distribution of GluR1 and significantly reduce hyperphosphorylation of GluR1 at serine 831 , which was closely associated with levodopa-induced motor complications. Conclusion: 8-OH-DPAT responses were probably mediated by 5-HT1A autoreceptor. Pharmaceuticals which act to stimulate 5-HT1A receptors may be useful in the treatment and prevention of the dyskinesias in parkinsonian patients.